Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1209)	1/7/2002 10:50:34 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1475

Nope. You bleed those who received the vaccine and fractionate the IgG antibody fraction from pooled plasma. The Eligix products are used to fractionate cell preparations. I presume that the donors would have their cells returned to them, but they'd be separated from the plasma by simple centrifugation. BTW..... this would provide very effective protection, and passive IgG has proven to be extremely safe.